5 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors

Page 5 of 5

1. AbbVie Inc. (NYSE:ABBV)

Holocene Advisors’ Stake Value: $195 million

Percentage of Holocene Advisors’ 13F Portfolio: 1.06%

Number of Hedge Fund Holders: 81

AbbVie Inc. (NYSE:ABBV) grabs the number 1 spot on the list for being the pharmaceutical company that Holocene Advisors is most heavily invested in relative to other pharma companies. It is another company on the list that is based in Illinois, US. It is focused on a variety of areas of research for drug development particularly for cystic fibrosis.  Holocene Advisors owns 1.8 million shares in the company as of Q3 of 2021. However, the leading stakeholder in the company was famous investor Warren Buffett’s Berkshire Hathaway with over 14 million shares in the third quarter. 

On November 17, Truist analyst Robyn Karnauskas pointed to a ClinicalTrials.gov posting on AbbVie’s Phase 2 study to analyze oral capsules of Galicaftor/Navocaftor/ABBV-119 in combination therapy in adults with Cystic Fibrosis, saying that the triple data could be pushed back a year or so according to an update posted on the site. The analyst has a ‘Buy’ rating on the company shares. AbbVie Inc. (NYSE:ABBV) posted a third quarter revenue of $14.34 billion with an EPS of $3.33 beating analyst estimates by $0.11.

You can also take a peek at the 10 Best Healthcare Stocks to Buy According to Hedge Funds and 10 Latest Stock Picks of Billionaire Ray Dalio.

Page 5 of 5